Review



calu-6  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC calu-6
    Calu 6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 546 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/custom%40htb-56%4042392088
    Average 96 stars, based on 546 article reviews
    calu-6 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Multiple Displacement Amplification:

    Article Title: MEK interactions tune RAF kinase sensitivity to conformation-selective inhibition.
    Article Snippet: Anti-Mek1 Antibody (Sigma-Aldrich, cat. no. 07-641)was validated to selectively bind Mek1 from A431 lysates by western blotting. .. Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) HEK-293T (ATCC, CRL-3216), Mia PaCa-2 (ATCC, CRL-1420), MDA-MB-453 (ATCC, HTB-131), SW480 (ATCC, CCL-228), DLD-1 (ATCC, CCL-221), MDA-MB-231 (ATCC, CRM-HTB-26), LoVo (ATCC, CCL-229), HPAF-II (ATCC, CRL-1997), AsPc-1 (ATCC, CRL-1682), A549 (ATCC, CRM-CCL-185), Calu-6 (ATCC, HTB-56), and HCT-116 (ATCC, CCL-247) Authentication Cell lines were sourced and authenticated by ATCC. ..

    other:

    Article Title: Brønsted-basic small molecules activate GTP hydrolysis in Ras Q61 mutants
    Article Snippet: Negative control is the phosphate sensor assay buffer and positive control is 2 μM Phosphate (diluted from 50 mM KH 2 PO 4 with 2 mM NaN 3 (Thermos Fisher Scientific #E6646,) The plate reader parameter is Excitation 430, Emission 450, Interval 1 min 30 s, Run time 4 h. For , NF1 was used as 1μM.

    Cell Culture:

    Article Title: Efficient identification of new small molecules targeting succinate dehydrogenase in non-small cell lung cancer.
    Article Snippet: .. Human lung EGFR-mutant cell lines (provided by Dr. Susumu Kobayashi in 2016) including HCC827, H3255, H1650, PC-9, PC-9ER (erlotinib resistant), and H1975, human lung KRAS-mutant cell lines (ATCC) including H358, H23, Calu-6, H441, A549 and H460, GFP-labelled H1975 and H358 cells, as well as primary mouse embryonic fibroblasts MEF-wt and MB352 (ATCC), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat#11995-40, Gibco) with 10% fetal bovine serum (FBS, Cat#F4135, MilliporeSigma), 2 mM L-glutamine and 1% penicillin-streptomycin. .. Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn in 2016) were derived as previously described [21] and maintained in SAGM media (Cat#CC-3118, Lonza).

    Article Title: Efficient identification of new small molecules targeting succinate dehydrogenase in non-small cell lung cancer
    Article Snippet: .. Human lung EGFR -mutant cell lines (provided by Dr. Susumu Kobayashi in 2016) including HCC827, H3255, H1650, PC-9, PC-9ER (erlotinib resistant), and H1975, human lung KRAS -mutant cell lines (ATCC) including H358, H23, Calu-6, H441, A549 and H460, GFP-labelled H1975 and H358 cells, as well as primary mouse embryonic fibroblasts MEF-wt and MB352 (ATCC), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat#11995-40, Gibco) with 10% fetal bovine serum (FBS, Cat#F4135, MilliporeSigma), 2 mM L-glutamine and 1% penicillin-streptomycin. .. Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn in 2016) were derived as previously described [ ] and maintained in SAGM media (Cat#CC-3118, Lonza).

    Modification:

    Article Title: Efficient identification of new small molecules targeting succinate dehydrogenase in non-small cell lung cancer.
    Article Snippet: .. Human lung EGFR-mutant cell lines (provided by Dr. Susumu Kobayashi in 2016) including HCC827, H3255, H1650, PC-9, PC-9ER (erlotinib resistant), and H1975, human lung KRAS-mutant cell lines (ATCC) including H358, H23, Calu-6, H441, A549 and H460, GFP-labelled H1975 and H358 cells, as well as primary mouse embryonic fibroblasts MEF-wt and MB352 (ATCC), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat#11995-40, Gibco) with 10% fetal bovine serum (FBS, Cat#F4135, MilliporeSigma), 2 mM L-glutamine and 1% penicillin-streptomycin. .. Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn in 2016) were derived as previously described [21] and maintained in SAGM media (Cat#CC-3118, Lonza).

    Article Title: Efficient identification of new small molecules targeting succinate dehydrogenase in non-small cell lung cancer
    Article Snippet: .. Human lung EGFR -mutant cell lines (provided by Dr. Susumu Kobayashi in 2016) including HCC827, H3255, H1650, PC-9, PC-9ER (erlotinib resistant), and H1975, human lung KRAS -mutant cell lines (ATCC) including H358, H23, Calu-6, H441, A549 and H460, GFP-labelled H1975 and H358 cells, as well as primary mouse embryonic fibroblasts MEF-wt and MB352 (ATCC), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat#11995-40, Gibco) with 10% fetal bovine serum (FBS, Cat#F4135, MilliporeSigma), 2 mM L-glutamine and 1% penicillin-streptomycin. .. Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn in 2016) were derived as previously described [ ] and maintained in SAGM media (Cat#CC-3118, Lonza).

    Mutagenesis:

    Article Title: Efficient identification of new small molecules targeting succinate dehydrogenase in non-small cell lung cancer
    Article Snippet: .. Human lung EGFR -mutant cell lines (provided by Dr. Susumu Kobayashi in 2016) including HCC827, H3255, H1650, PC-9, PC-9ER (erlotinib resistant), and H1975, human lung KRAS -mutant cell lines (ATCC) including H358, H23, Calu-6, H441, A549 and H460, GFP-labelled H1975 and H358 cells, as well as primary mouse embryonic fibroblasts MEF-wt and MB352 (ATCC), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Cat#11995-40, Gibco) with 10% fetal bovine serum (FBS, Cat#F4135, MilliporeSigma), 2 mM L-glutamine and 1% penicillin-streptomycin. .. Immortalized tracheobronchial epithelial AALE cells (provided by Dr. William C. Hahn in 2016) were derived as previously described [ ] and maintained in SAGM media (Cat#CC-3118, Lonza).



    Similar Products

    calu-6  (ATCC)
    96
    ATCC calu-6
    Calu 6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/custom%40htb-56%4042392088
    Average 96 stars, based on 1 article reviews
    calu-6 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    human lung cancer cell line calu  (ATCC)
    96
    ATCC human lung cancer cell line calu
    Human Lung Cancer Cell Line Calu, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/us12648946-1146-1-9
    Average 96 stars, based on 1 article reviews
    human lung cancer cell line calu - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    calu 6 cells  (ATCC)
    96
    ATCC calu 6 cells
    Calu 6 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/pm42219118-52-0-6
    Average 96 stars, based on 1 article reviews
    calu 6 cells - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    calu 6  (ATCC)
    96
    ATCC calu 6
    Calu 6, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/pm42120500-1027-48-49
    Average 96 stars, based on 1 article reviews
    calu 6 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    cells  (ATCC)
    96
    ATCC cells
    Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/pmc13049657-368-8-9
    Average 96 stars, based on 1 article reviews
    cells - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    calu  (ATCC)
    96
    ATCC calu
    Peptide design and evaluation (A) Schematic representation of SARS-CoV-2 spike protein and amino acid sequences of HR2 peptides from SARS-CoV-2 and EK1 (HCoV-OC43 HR2 derived peptide). N , N-terminus ; C , C-terminus ; S1/S2 , cleavage site at S1/S2 boundary ; RBD , receptor-binding domain ; HR1 , heptad repeat 1 ; HR2 , heptad repeat 2 ; HR2P , heptad repeat 2 peptide. Syncytia assay. Left: GFP- and spike-expressing 293T cells were co-cultured with RFP- and <t>ACE2-expressing</t> <t>Calu-6</t> cells for 16 h in the presence or absence of peptides. Center: double-positive cells (white arrows) indicative of syncytia formation are frequent in the presence of the scrambled EK1 peptide (Ⅰ) but not in the presence of CGM23 (Ⅱ) (100 nM). Right: quantification of syncytia formation in the presence of the scrambled EK1 peptide (top) or CGM23 (bottom) relative to mock treatment. (B) Sequence, N- and C-terminal modifications and IC 50 of the 15 peptides with IC 50 s < 10 nM in the syncytia assay. CoV-2, SARS-CoV-2; N-term, N-terminus; C-term, C-terminus. IC 50 data are means of samples from a representative experiment. Ac, acetylation; PPA, 4-phenylpropanoic acid; PBA, 4-phenylbutanonic acid. (C) Correlation between IC 50 values in the pseudotyped SARS-CoV-2 spike virion assay and live SARS-CoV2 virus infection assay for the 15 peptides with IC 50 values below 10 nM in the syncytia assay. Statistical analysis was performed using Spearman’s rank test. (D and E) Dose-dependent inhibitory activity of CGM23 and EK1C4 relative to CG167 (EK1 scrambled peptide with EK1C4 lipidation) in the pseudotyped SARS-CoV2 spike virion assay (D) and live SARS-CoV2 infection assay (E). IC 50, half-maximal inhibitory concentration.
    Calu, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/pmc13049657-368-6-9
    Average 96 stars, based on 1 article reviews
    calu - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    calu 3  (ATCC)
    96
    ATCC calu 3
    Peptide design and evaluation (A) Schematic representation of SARS-CoV-2 spike protein and amino acid sequences of HR2 peptides from SARS-CoV-2 and EK1 (HCoV-OC43 HR2 derived peptide). N , N-terminus ; C , C-terminus ; S1/S2 , cleavage site at S1/S2 boundary ; RBD , receptor-binding domain ; HR1 , heptad repeat 1 ; HR2 , heptad repeat 2 ; HR2P , heptad repeat 2 peptide. Syncytia assay. Left: GFP- and spike-expressing 293T cells were co-cultured with RFP- and <t>ACE2-expressing</t> <t>Calu-6</t> cells for 16 h in the presence or absence of peptides. Center: double-positive cells (white arrows) indicative of syncytia formation are frequent in the presence of the scrambled EK1 peptide (Ⅰ) but not in the presence of CGM23 (Ⅱ) (100 nM). Right: quantification of syncytia formation in the presence of the scrambled EK1 peptide (top) or CGM23 (bottom) relative to mock treatment. (B) Sequence, N- and C-terminal modifications and IC 50 of the 15 peptides with IC 50 s < 10 nM in the syncytia assay. CoV-2, SARS-CoV-2; N-term, N-terminus; C-term, C-terminus. IC 50 data are means of samples from a representative experiment. Ac, acetylation; PPA, 4-phenylpropanoic acid; PBA, 4-phenylbutanonic acid. (C) Correlation between IC 50 values in the pseudotyped SARS-CoV-2 spike virion assay and live SARS-CoV2 virus infection assay for the 15 peptides with IC 50 values below 10 nM in the syncytia assay. Statistical analysis was performed using Spearman’s rank test. (D and E) Dose-dependent inhibitory activity of CGM23 and EK1C4 relative to CG167 (EK1 scrambled peptide with EK1C4 lipidation) in the pseudotyped SARS-CoV2 spike virion assay (D) and live SARS-CoV2 infection assay (E). IC 50, half-maximal inhibitory concentration.
    Calu 3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/calu+6/Calu-6/pm41839471-108-0-1
    Average 96 stars, based on 1 article reviews
    calu 3 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Peptide design and evaluation (A) Schematic representation of SARS-CoV-2 spike protein and amino acid sequences of HR2 peptides from SARS-CoV-2 and EK1 (HCoV-OC43 HR2 derived peptide). N , N-terminus ; C , C-terminus ; S1/S2 , cleavage site at S1/S2 boundary ; RBD , receptor-binding domain ; HR1 , heptad repeat 1 ; HR2 , heptad repeat 2 ; HR2P , heptad repeat 2 peptide. Syncytia assay. Left: GFP- and spike-expressing 293T cells were co-cultured with RFP- and ACE2-expressing Calu-6 cells for 16 h in the presence or absence of peptides. Center: double-positive cells (white arrows) indicative of syncytia formation are frequent in the presence of the scrambled EK1 peptide (Ⅰ) but not in the presence of CGM23 (Ⅱ) (100 nM). Right: quantification of syncytia formation in the presence of the scrambled EK1 peptide (top) or CGM23 (bottom) relative to mock treatment. (B) Sequence, N- and C-terminal modifications and IC 50 of the 15 peptides with IC 50 s < 10 nM in the syncytia assay. CoV-2, SARS-CoV-2; N-term, N-terminus; C-term, C-terminus. IC 50 data are means of samples from a representative experiment. Ac, acetylation; PPA, 4-phenylpropanoic acid; PBA, 4-phenylbutanonic acid. (C) Correlation between IC 50 values in the pseudotyped SARS-CoV-2 spike virion assay and live SARS-CoV2 virus infection assay for the 15 peptides with IC 50 values below 10 nM in the syncytia assay. Statistical analysis was performed using Spearman’s rank test. (D and E) Dose-dependent inhibitory activity of CGM23 and EK1C4 relative to CG167 (EK1 scrambled peptide with EK1C4 lipidation) in the pseudotyped SARS-CoV2 spike virion assay (D) and live SARS-CoV2 infection assay (E). IC 50, half-maximal inhibitory concentration.

    Journal: iScience

    Article Title: CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion

    doi: 10.1016/j.isci.2026.115334

    Figure Lengend Snippet: Peptide design and evaluation (A) Schematic representation of SARS-CoV-2 spike protein and amino acid sequences of HR2 peptides from SARS-CoV-2 and EK1 (HCoV-OC43 HR2 derived peptide). N , N-terminus ; C , C-terminus ; S1/S2 , cleavage site at S1/S2 boundary ; RBD , receptor-binding domain ; HR1 , heptad repeat 1 ; HR2 , heptad repeat 2 ; HR2P , heptad repeat 2 peptide. Syncytia assay. Left: GFP- and spike-expressing 293T cells were co-cultured with RFP- and ACE2-expressing Calu-6 cells for 16 h in the presence or absence of peptides. Center: double-positive cells (white arrows) indicative of syncytia formation are frequent in the presence of the scrambled EK1 peptide (Ⅰ) but not in the presence of CGM23 (Ⅱ) (100 nM). Right: quantification of syncytia formation in the presence of the scrambled EK1 peptide (top) or CGM23 (bottom) relative to mock treatment. (B) Sequence, N- and C-terminal modifications and IC 50 of the 15 peptides with IC 50 s < 10 nM in the syncytia assay. CoV-2, SARS-CoV-2; N-term, N-terminus; C-term, C-terminus. IC 50 data are means of samples from a representative experiment. Ac, acetylation; PPA, 4-phenylpropanoic acid; PBA, 4-phenylbutanonic acid. (C) Correlation between IC 50 values in the pseudotyped SARS-CoV-2 spike virion assay and live SARS-CoV2 virus infection assay for the 15 peptides with IC 50 values below 10 nM in the syncytia assay. Statistical analysis was performed using Spearman’s rank test. (D and E) Dose-dependent inhibitory activity of CGM23 and EK1C4 relative to CG167 (EK1 scrambled peptide with EK1C4 lipidation) in the pseudotyped SARS-CoV2 spike virion assay (D) and live SARS-CoV2 infection assay (E). IC 50, half-maximal inhibitory concentration.

    Article Snippet: Live virus experiments were performed with Calu-6 epithelial cells (ATCC HTB-56) stably expressing human Angiotensin Converting Enzyme 2 (ACE2) (OriGene, RC08442) as target cells.

    Techniques: Derivative Assay, Binding Assay, Expressing, Cell Culture, Sequencing, Virus, Infection, Activity Assay, Concentration Assay

    In vivo prophylactic and therapeutic efficacy of CGM23 against SARS-CoV-2 live virus in mice (A) The SARS-CoV-2 outgrowth assay. Lung homogenates were collected 2 days post viral infection (DPI) combined with intranasal administration of CGM23 and EK1C4 (12.5 μg, 0.865 mg/kg). (B) Diluted lung homogenates were added to Calu-6-ACE2 cells and infection titers were measured by the luciferase assay 48 h later. CG167, EK1 scrambled peptide with EK1C4 lipidation. Data presented correspond to mean ± SD. ∗ p < 0.05. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. (C) Histopathological findings of mouse lungs at 2 days after virus inoculation. Images are shown clockwise starting from the top left: CG167 group, EK1C4 group, non-infected group, and CGM23 group. Lung sections were stained with anti-spike antibody (green) and anti-MAC-2 antibody (magenta) and DAPI (blue). Scale bars, 100μm. (D and E) Quantitative analysis of lung histopathological findings for each group. Data shown represent means ± SD. (F) Therapeutic treatment. CGM23 and EK1C4 were administered intranasally (12.5 μg, 0.865 mg/kg; 25 μg, 1.73 mg/kg) 8 h after SARS-CoV-2 inoculation, and lung homogenates were collected 24 h later for plaque assay analysis. Data presented correspond to mean ± SD. ∗ p < 0.05, ∗∗∗ p < 0.001. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. (G) Prophylactic treatment. SARS-CoV-2 was administered intranasally 30 min after intranasal administration of CGM23 or EK1C4 (12.5 μg, 0.865 mg/kg; 25 μg, 1.73 mg/kg). Lung tissues were collected 24 h later for plaque assay analysis.

    Journal: iScience

    Article Title: CGM23 corresponds to a pan-coronavirus lipopeptide inhibitor potently inhibiting virion fusion

    doi: 10.1016/j.isci.2026.115334

    Figure Lengend Snippet: In vivo prophylactic and therapeutic efficacy of CGM23 against SARS-CoV-2 live virus in mice (A) The SARS-CoV-2 outgrowth assay. Lung homogenates were collected 2 days post viral infection (DPI) combined with intranasal administration of CGM23 and EK1C4 (12.5 μg, 0.865 mg/kg). (B) Diluted lung homogenates were added to Calu-6-ACE2 cells and infection titers were measured by the luciferase assay 48 h later. CG167, EK1 scrambled peptide with EK1C4 lipidation. Data presented correspond to mean ± SD. ∗ p < 0.05. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. (C) Histopathological findings of mouse lungs at 2 days after virus inoculation. Images are shown clockwise starting from the top left: CG167 group, EK1C4 group, non-infected group, and CGM23 group. Lung sections were stained with anti-spike antibody (green) and anti-MAC-2 antibody (magenta) and DAPI (blue). Scale bars, 100μm. (D and E) Quantitative analysis of lung histopathological findings for each group. Data shown represent means ± SD. (F) Therapeutic treatment. CGM23 and EK1C4 were administered intranasally (12.5 μg, 0.865 mg/kg; 25 μg, 1.73 mg/kg) 8 h after SARS-CoV-2 inoculation, and lung homogenates were collected 24 h later for plaque assay analysis. Data presented correspond to mean ± SD. ∗ p < 0.05, ∗∗∗ p < 0.001. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. (G) Prophylactic treatment. SARS-CoV-2 was administered intranasally 30 min after intranasal administration of CGM23 or EK1C4 (12.5 μg, 0.865 mg/kg; 25 μg, 1.73 mg/kg). Lung tissues were collected 24 h later for plaque assay analysis.

    Article Snippet: Live virus experiments were performed with Calu-6 epithelial cells (ATCC HTB-56) stably expressing human Angiotensin Converting Enzyme 2 (ACE2) (OriGene, RC08442) as target cells.

    Techniques: In Vivo, Drug discovery, Virus, Infection, Luciferase, Staining, Plaque Assay